Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny placental particles may hold key to pregnancy complications

NCT ID NCT07470320

Knowledge-focused Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study looks at how tiny particles released by the placenta, called extracellular vesicles, affect pregnancy complications like pre-eclampsia and gestational diabetes. Researchers will collect samples from 360 pregnant and non-pregnant women to understand these particles better. The goal is to find new ways to detect and treat these conditions early, improving health for mothers and babies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 360 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will recruit a diverse cohort of pregnant and non-pregnant participants to enable analysis of placental EVs and soluble factors across different physiological and pathological conditions. Participants will include: * Pregnant women with pre-eclampsia, gestational diabetes mellitus or fetal growth restriction to allow the study of disease-specific alterations in EVs and systemic responses. * Pregnant women predisposed to pre-eclampsia to provide insights into risk factors and early-stage changes, aiding in biomarker discovery for prediction and prevention. * Pregnant women with healthy pregnancies to understand normal EV release and immune regulation. * Non-pregnant women to provide critical baseline data to differentiate the effects of pregnancy from underlying physiological processes. Pregnant participants may be recruited at any gestational stage to ensure a comprehensive coverage of pregnancy progression.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female, aged 18 years or above * Willing and able to give informed consent for participation in the study * Able to read and understand written and spoken English to comprehend study materials and give informed consent * Non-pregnant women in good general health OR pregnant women who fall into one of the following: * Healthy pregnancy * Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria * Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy * Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities * Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies Exclusion Criteria: * Non-pregnant participants with active health conditions that could confound study outcomes * Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fetal growth restriction (FGR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fetal growth restriction gestational diabetes hypertension, pregnancy-induced placenta disorder preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fetal growth restriction (FGR) Gestational diabetes mellitus (GDM) Placenta Pre-eclampsia Pregnancy Pregnancy induced hypertension (PIH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Oxford University Hospitals NHS Foundation Trust

    RECRUITING

    Oxford, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.